{
    "id": 5744,
    "name": "ovary serous adenocarcinoma",
    "source": "DOID",
    "definition": "An ovary adenocarcinoma that derives_from the lining of a cavity that produces a serum-like fluid (a serous cavity). [url:http\\://en.wikipedia.org/wiki/Adenocarcinoma, url:http\\://en.wikipedia.org/wiki/Serous_carcinoma]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        "5745"
    ],
    "termId": "DOID:5744",
    "evidence": [
        
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT01853306",
            "title": "A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 954,
                    "therapyName": "Veliparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02282020",
            "title": "Olaparib Treatment in Relapsed Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments.",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 837,
                    "therapyName": "Olaparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02316834",
            "title": "POSITION: A PilOt Study of InducTion PARP InhibitiON in Ovarian Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 682,
                    "therapyName": "Talazoparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02345265",
            "title": "Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1971,
                    "therapyName": "Cediranib + Olaparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02354586",
            "title": "A Study of Niraparib in Patients With Ovarian Cancer Who Have Received at Least Three Previous Chemotherapy Regimens",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 832,
                    "therapyName": "Niraparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02584478",
            "title": "Phase 1/2a Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7370,
                    "therapyName": "Anlotinib + Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03277209",
            "title": "To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1756,
                    "therapyName": "Plerixafor",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03737643",
            "title": "Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients. (DUO-O)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1152,
                    "therapyName": "Bevacizumab + Carboplatin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 7489,
                    "therapyName": "Bevacizumab + Carboplatin + Durvalumab + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 7490,
                    "therapyName": "Bevacizumab + Durvalumab + Olaparib",
                    "synonyms": null
                },
                {
                    "id": 837,
                    "therapyName": "Olaparib",
                    "synonyms": null
                },
                {
                    "id": 2117,
                    "therapyName": "Bevacizumab + Durvalumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03839524",
            "title": "A Trial Evaluating TG4050 in Ovarian Carcinoma.",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9165,
                    "therapyName": "TG4050",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04149145",
            "title": "Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian Cancer",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9153,
                    "therapyName": "Niraparib + VX-803",
                    "synonyms": null
                }
            ]
        }
    ]
}